Medical Research Technology Offers

Maria João Cardoso posted this:
Science and Technology Manager at UATEC - Unidade de Transferência de Tecnologia

Magnetic nanoparticles for selective enrichment of proteins in complex mixtures New method for preparing ion chelating magnetic nanoparticles, which allow selective protein enrichment, namely metalloproteases (MMPs) and His-tagged proteins, from complex mixtures.

Universidad de Alcalá-OTRI posted this:

Compounds for the treatment of Leishmania infections The research group Heterobetainas of the University of Alcalá presents the preparation and uses of a series of compounds that act as bioactive agents against the Leishmania parasite and as therapeutic agents in the treatment of this disease, in both, its visceral (LV) version and in the mucocutaneous one (CML). The group is looking for pharmaceutical companies interested in manufacturing an active ingredient for the formulation of a leishmanicidal drug based on these compounds. The group proposes the signing of a patent license agreement, a collaboration agreement or a commercial agreement with technical

Universidad de Alcalá-OTRI posted this:

Endothelial microvesicles with microbicidal effect for the preparation of a medicament or for a direct use The research group "Cell damage associated with senescence" of the University of Alcalá presents the microbicidal capacity of endothelial microvesicles. These vesicles destroy the main pathogens involved in sepsis and even strains derived from them resistant to multiple antibiotics. They have also been shown to be effective against the biofilms that form these microorganisms. The group seeks to reach licensing agreements, cooperation or commercial agreements with technical assistance, with pharmaceutical companies interested in the design of new medicines.

Mª Eugenia Garcés Castellote posted this:
Commercialization Specialist at Universidad de Alcalá-OTRI

New inhibitor compounds of the tyrosine phosphatase 1B protein The research group in "Biological Chemistry" of the University of Alcalá has developed new compounds inhibitors of the Tyrosine Phosphatase 1B Protein, which are related to new Formulas I, II and III, with methods to prepare them, with the use of them as inhibitors of protein tyrosine phosphatase 1B (PTP1B) and with the use of the intermediates that lead to that compounds to prepare an inhibitor of PTP1B comprised by that formulas. These compounds have application in the treatment or prevention of diseases in which it is known that PTP1B is involved in the pathogenesis, so they can be used for the treatment of insulin resistance, glucose intolerance, obesity, diabetes mellitus, hypertension and ischemic diseases of large and small blood vessels, conditions that accompany type 2 diabetes and other disorders where insulin resistance is indicated. The group looks for companies in the health and pharmaceutical sector with the aim of reaching technical collaboration agreements, commercial agreements or patent licenses agreements.

Universidad de Alcalá-OTRI posted this:

Carbosilane dendrons functionalized with fatty acids: Formation of micelles and uses in biomedicine as antiviral, antibacterial, antiprionic, antimicrobial and drug transporters.The research group of the University of Alcalá in «Dendrimers for biomedical applications» presents the following invention that refers to the formation of dendrons of carbosilane structure that have in their periphery preferably anionic or cationic groups and in the focal point fatty acids or derivatives of these. Its main field of application is in biomedicine, as non-viral transport agents, as drug transporters, to elaborate a drug, as antimicrobial, antiviral or antipyretic agents. In the environmental sector we also find its application as biocides for water treatment. The group seeks to reach license agreements, collaboration or commercial agreements with technical assistance with companies from the sector of Health, Pharma and Environment.

Universidad de Alcalá-OTRI posted this:

Carbosilane dendrimers with terminal thiol groups on their surface. Their preparation and their uses.The research group in «Dendrimers for biomedical applications» of the University of Alcalá presents the procedure for obtaining and using carbosilane dendrimers with terminal thiol groups on their surface, as antioxidants and radical scavengers for their application in the food industry, cosmetic and pharmaceutical. The group seeks to reach licensing agreements, collaboration agreements or commercial agreements with technical assistance, with enterprises from the food industry, cosmetic, biotechnology, Biomedicine or pharmaceutical sector.

Universidad de Alcalá-OTRI posted this:

Carbosilane dendrimers with a polyphenolic nucleus and their use as antivirals The research group in «Dendrimers for biomedical applications» of the University of Alcalá presents carbosilane dendrimers with a polyphenolic nucleus, its obtaining procedure and its uses as antiviral, antibacterial and antifungal agents. The group seeks to reach collaboration agreements, licensing or commercial agreements with technical assistance, with companies from the biotechnology, pharmaceutical and biomedicine sectors in general.

Universidad de Alcalá-OTRI posted this:

Carbosilane dendrimers and their use as antivirals The research group in "Dendrimers for Biomedical Applications" of the University of Alcalá presents these highly branched macromolecules synthesized from a polyfunctional nucleus, of carbosilane structure and functionalized in its periphery with anionic groups that give the macromolecule a negative net charge. In addition, the invention relates to the use of the dendrimers as an antimicrobial and the process for obtaining them. The group seeks to reach collaboration agreements, licensing or commercial agreements with technical assistance, with companies in the biotechnology, pharmaceutical and biomedicine sectors in general.

Merck KGaA posted this:

Technology for Lysophosphatidic Acid (LPA) Receptor antagonists Merck has developed and patented the results of its intense R&D activities for the identification of small organic molecules as antagonists to certain LPA receptors (LPAR1, -R2, -R3). Herein described are LPA-R2 receptor selective inhibitors. Based upon a rational screening cascade established, compounds have been identified and characterized with regard to their specific in vitro and cellular activities. The package includes access to the IP, experimental results, and materials. Merck offers the unique chance to acquire this promising program.

Merck KGaA posted this:

Novel Pharmaceutical Salt Forming Counterions with Increased Dissolution Rates and Supersaturation One of the major obstacles in developing promising New Chemical Entities (NCEs) as Active Pharmaceutical Ingredients (APIs) is their low solubility and therefore poor bioavailability. Merck has developed a novel class of salt forming anions as counter-ions for protonated free base APIs which result in an accelerated dissolution rate and increased solubility by supersaturation of the NCE. The invention is based on a systematic thermodynamic and molecular engineering approach to design the above mentioned anions resulting in crystal lattices of API salts with weak Coulomb interactions.

Universidad de Alcalá-OTRI posted this:

Method of diagnosis of non-invasive renal failure and prior to symptoms and functional disorders The Renal Nephropathy research group at the University of Alcalá presents a method of diagnosis of Renal Insufficiency (RI), in all varieties of the disease, that determines the amount of protein related to parathyroid hormone (PTHrP) present in a sample of urine, comparing said amount with at least one reference value and diagnosing RI from said comparison. The research group seeks companies from the diagnostic medicine, biomedicine or pharmacy sector to establish licensing agreements, collaboration agreements or commercial agreements with technical assistance.

Agro Biotech International Exports Pvt. Lt. posted this:

White turmeric (Curcuma aromatica Salisb) is a multi face herbal White Turmeric (Curcuma aromatica Salisb) is a multi faced herbal used in the Cosmetic industries to cancer research institutes. We have the sufficiant raw materials for export. It is used for anti fertility usage. The practice of traditional medicine for the control of fertility in most parts of India is based on the uses of plant medicines for many years. Anti-inflammatory and wound healing activity of topical application of Curcuma aromatica Salisb.

Universitat de Lleida posted this:

Treatment and prevention of Amyotrophic Lateral Sclerosis A group of researchers in the University of Lleida have preclinical evidence for the positive effects of a peptide administration in the mouse model for ALS (mSOD1G93A mice). When treated with a solution containing interleukin-4 polypeptide (IL4), the team is able to prolong survival, delay the manifestation of the most apparent symptoms of the disease and improve the clinical course of the disease attenuating body weight loss and improving the motor behavior. The University of Lleida seeks an industrial partner willing to further develop this technology under a license agreement.

Universidad de Alcalá-OTRI posted this:

Carbosilane dendrimers with polyphenolic groups. Uses as antioxidants and anticancer.The "Dendrimer for biomedical applications Research Group" at Alcalá University presents dendritic macromolecules with skeleton of carbosilane nature that contain in their structure polyphenolic groups (GPF). These compounds are powerful antioxidants and free radical scavengers, as well as anticancer agents, with application in sectors such as food, cosmetics and pharmaceutical industry. The invention provides a process for its procurance and uses.

Germans Trias i Pujol Health Sciences Research Institute posted this:

Apotransferrin to treat stroke Our group has demonstrated that intravenous administration of apotransferrin strongly reduces the brain damage (up to 75%) in 3 different rat models including both transient and permanent ischemic stroke and improves the neurological impairment (neuroscore 60%) induced by stroke. Thus, this new approach may benefit not only stroke patients who can be treated with current treatment to induce recanalization (transient stroke) but also the 80% of patients who could not benefit from current therapies directed to induce recanalization of the artery (permanent strokes). Results in the preclinical area and some results obtained in serum of stroke patients lead us to think that apotransferrin is a good neuroprotector in the early stages of the ischemic event.

Medical Research Technology Offers

Innovation Resources

Sitemaps

Support

Company

Top Posts Categories

Recognitions

Log in to find novel technologies and contact researchers

Medical Research Technology Offers

Recognitions

Follow us

Log in to find novel technologies and contact researchers